You’ve tried two antidepressants. Then a third. Maybe a fourth. Each time, you waited weeks for something to shift, and each time the relief either never came or faded too quickly to matter. Now someone has mentioned TMS therapy, and the first question you’re asking is a reasonable one: does this actually work?
That question deserves a straight answer, not a sales pitch. TMS does produce real results for many people with treatment-resistant depression, and the clinical evidence behind it is substantial. At the same time, the TMS success rate requires more context than a single number can provide, because researchers measure “success” in two distinct ways: response and remission. These aren’t interchangeable, and confusing them leads to either inflated or deflated expectations. A patient who responds to TMS may feel far better without being fully symptom-free; a patient in remission has crossed a higher threshold entirely. Here’s what the clinical data shows, who tends to benefit most, what influences your individual outcome, and what to ask before you start.
When clinicians and researchers cite a TMS success rate, they’re almost always referring to one of two outcomes drawn from standardized psychiatric research methodology.
Response means a large reduction in symptom severity, typically a 50% or greater decrease in scores on validated depression scales such as the PHQ-9, the Hamilton Depression Rating Scale (HAM-D), or the Montgomery-Asberg Depression Rating Scale (MADRS). A patient who responds has had their symptoms roughly cut in half. That usually translates to better functioning, improved sleep, more energy, and greater ability to engage with daily life, but it doesn’t necessarily mean the person feels well in an absolute sense.
Remission is a higher bar: scoring below a clinical threshold that indicates minimal or no remaining symptoms. On the PHQ-9, remission is often defined as a score of four or lower; on the HAM-D-17, seven or below. A patient in remission isn’t just better than they were. They are, by clinical definition, nearly or fully symptom-free.
This distinction matters because published figures look quite different depending on which metric a study reports. A study reporting a 55% response rate and one reporting a 33% remission rate may describe the same group of patients measured two ways. Neither number is misleading on its own, but reading one without the other gives an incomplete picture.
Remission is generally the gold standard in depression research. Response is still a valuable outcome, particularly for patients living with severe, chronic symptoms, for whom a 50% reduction in burden is a major change in quality of life. Many patients who achieve response rather than full remission still describe TMS as one of the most helpful treatments they’ve tried.
The practical takeaway: when you see a headline claiming a certain TMS success rate, ask if that number reflects response, remission, or some combination. The answer changes how you should interpret the data and calibrate your expectations.
TMS received FDA clearance for major depressive disorder in 2008, based on a randomized controlled trial of NeuroStar Advanced Therapy. That clearance established TMS as a legitimate, evidence-backed option for patients who hadn’t responded adequately to antidepressants, and the research base has grown considerably since.
One of the most frequently cited real-world datasets comes from the NeuroStar TMS Therapy Patient Registry, a large naturalistic study tracking outcomes in ordinary clinical practice rather than controlled trial conditions. Registry data matters because it reflects real patients with complex histories, variable medication backgrounds, and imperfect adherence.
Across the peer-reviewed literature, including studies in the Journal of Clinical Psychiatry and the Journal of Affective Disorders, the TMS response rate for major depressive disorder is generally reported around 50 to 60 percent, and the remission rate around 30 to 37 percent. These ranges come mostly from studies of treatment-resistant depression, meaning people who hadn’t found adequate relief from at least one or two prior antidepressant trials.
Pause on those numbers. For a population where medication has already fallen short, a 50 to 60 percent response rate is a strong result. These are patients for whom standard pharmacology failed, and a substantial share of them are getting real symptom reduction through TMS.
Durability matters too. Published studies suggest a solid proportion of TMS responders maintain their improvement for months after completing a standard course, with some research showing sustained benefit at the 12-month mark. Durability varies by person, and some patients benefit from maintenance sessions over time, but the evidence doesn’t support the idea that TMS effects are purely temporary.
Newer protocols have expanded the options. Intermittent theta burst stimulation, or iTBS, is an FDA-cleared protocol delivering treatment in much shorter sessions than traditional repetitive TMS, and published studies, including a large non-inferiority trial, found iTBS produces comparable response and remission rates to standard rTMS. That has made TMS more workable for patients who find longer daily sessions hard to manage.
The success rate isn’t uniform across patients, and knowing which characteristics correlate with better outcomes helps set realistic expectations.
Patients with fewer prior medication failures generally respond better than those with longer histories of treatment resistance, which makes clinical sense: the more entrenched and complex the history, the harder remission becomes through any single intervention. Someone trying TMS after one or two failed antidepressant trials is in a different position than someone who has been through eight or ten medications over many years.
Completing the full treatment course is another strong predictor. TMS typically runs about 36 sessions across six to nine weeks, and patients who finish the protocol do better than those who stop early. This matters when reading the data too: naturalistic studies often include incomplete courses in their datasets, which can pull population-level numbers below what completers actually experience.
Diagnosis matters as well. TMS is FDA-cleared for major depressive disorder and for obsessive-compulsive disorder. For depression, the evidence base is strong and well established. For OCD, TMS uses a different coil configuration targeting different circuitry, and the outcomes data, while promising, reflects a smaller body of research. For anxiety disorders or PTSD, TMS is sometimes used as an adjunct, but the evidence is still developing, and patients seeking TMS for these conditions should have a frank conversation with their provider about what the research does and doesn’t support.
Comorbid conditions can shift the picture too. Heavy anxiety alongside depression, or active substance use, may change response trajectories. That doesn’t rule out TMS, but it’s a reason the clinical team needs your complete history before building a plan. TMS isn’t one-size-fits-all, and a thorough evaluation before starting treatment is one of the most important steps toward a good outcome.
Beyond patient characteristics, several treatment-level variables affect how well TMS works, which helps explain why outcomes vary even among patients who look similar on paper.
The protocol is one. Standard rTMS typically delivers 3,000 to 4,000 pulses per session over 20 to 40 minutes; theta burst delivers a similar therapeutic effect in three to ten minutes. Both are FDA-cleared with demonstrated efficacy. Deep TMS using an H-coil targets deeper brain structures and is cleared for depression and OCD. The choice should follow clinical judgment and your specific presentation, not convenience.
Coil placement precision is another. Traditional placement relies on anatomical landmarks to position the coil over the left dorsolateral prefrontal cortex, the primary depression target. More advanced approaches use brain mapping or quantitative EEG (qEEG) to personalize placement based on your individual brain activity. Some clinicians find individualized targeting improves outcomes by reaching the most relevant circuits, though research in this area continues to refine best practices.
Concurrent care plays a role as well. Patients receiving TMS alongside medication management, psychotherapy, or neurofeedback may see different outcomes than those using TMS alone. That isn’t a knock on TMS by itself; depression is complex, and a coordinated, multimodal approach often reaches further than any single intervention. Some patients find TMS creates a neurological window of improved responsiveness that makes other therapies land harder during and after the course.
The most controllable factor of all: finishing the recommended course. Stopping early, from scheduling problems, discouragement, or side effects, sharply reduces the odds of response. TMS effects are cumulative, many patients notice little change until the third or fourth week, and some see the full benefit only after the course ends. Getting the timeline straight before treatment begins is part of any good clinical conversation.
For treatment-resistant depression, several evidence-based options exist, and TMS sits within that context.
Antidepressants work well for many people, but their effectiveness drops sharply in patients who have already failed medication trials; research consistently shows each successive trial carries lower response rates than the one before. That’s not a reason to abandon medication, but it’s the clinical context that makes TMS a relevant alternative rather than a last resort.
TMS is a non-systemic treatment. Because stimulation is applied directly through the scalp, it doesn’t circulate through the body like a medication, so it avoids the systemic side effects commonly tied to antidepressants: weight changes, sexual dysfunction, gastrointestinal issues, sedation. The most common TMS side effects are scalp discomfort and headache during or shortly after sessions, which typically fade within the first week. Seizure risk exists but is very rare under established safety guidelines.
Ketamine infusions and SPRAVATO (esketamine) nasal spray are other evidence-based options. They work through a different mechanism and act faster, sometimes within hours or days, but involve different protocols, monitoring requirements, and questions around ongoing use. Some patients and clinicians use ketamine or SPRAVATO and TMS in a coordinated plan, particularly when rapid relief is needed while TMS’s longer-acting effects develop.
What TMS is not is a guaranteed solution. Some patients don’t respond, and some who respond see symptoms return over time. A provider who tells you TMS works for everyone isn’t giving you accurate information. A provider who helps you understand your individual likelihood of benefit, based on your history and presentation, is giving you something far more useful.
Going into your first consultation with clear questions gets you better information and a more confident decision.
Ask about the specific protocol: standard rTMS, theta burst, or deep TMS? How many sessions, on what schedule? Ask how progress will be measured. A good clinical team uses validated symptom scales at regular intervals throughout the course, not just at the start and end; if a clinic can’t explain how it monitors progress, take note. Ask what happens if your response is partial. Some patients improve substantially but don’t reach full remission after a standard course, and in those cases options include extending the course, adjusting the protocol, or adding a complementary treatment. Knowing there’s a plan for partial response takes anxiety out of the middle weeks.
Most importantly, ask about the psychiatric evaluation before treatment begins. A thorough evaluation covers your complete medication history, a current diagnostic assessment, and any comorbid conditions that might shape the plan. TMS works best inside a carefully constructed clinical picture, not layered on top of an incomplete one.
The TMS success rate isn’t a single number. It’s a range of outcomes measured two ways: response, a major reduction in symptoms, generally reported at 50 to 60 percent, and remission, near-complete resolution, generally reported at 30 to 37 percent, both in patients whose depression had already resisted medication. In that population, those figures are strong, not modest.
Your individual result depends on your treatment history, the protocol used, the consistency of your attendance, and how TMS fits into your broader care plan. Those are exactly the things a proper evaluation sorts out. If you’ve been living with depression that hasn’t responded to medication, or you want a non-pharmacological path forward, TMS deserves a serious conversation with a qualified clinical team. Reach out to our team at Delray Brain Science to schedule a consultation, or explore our full range of treatments on our homepage. You deserve a clear answer on TMS as your next step, and we’ll help you get one.
